Search
vemurafenib (Zelboraf, PLX4032)
Indications:
- metastatic melanoma (BRAF V600E positive)*
- Erdheim-Chester disease (BRAF V600E positive)
- craniopharyngioma*
* for use in combination with cobimetinib
Adverse effects:
- rash
- photosensitivity
- uveitis (10%) [3]
- joint pain
- hair loss
- fatigue
- cutaneous squamous cell carcinoma
Laboratory:
- BRAF V600E mutation
Mechanism of action:
- BRAF inhibitor
- designed to selectively target & inhibit a mutated form of BRAF
General
small inhibitory antineoplastic agent (ib drug)
Database Correlations
PUBCHEM cid=42611257
References
- New Drug Applications
http://www.roche.com/med-cor-2011-05-11-e.pdf
- FDA NEWS RELEASE: Aug. 17, 2011
FDA approves Zelboraf and companion diagnostic test for
late-stage skin cancer
- Guedj M et al.
Uveitis in patients with late-stage cutaneous melanoma treated
with vemurafenib.
JAMA Opthalmol 2014 Aug 14
PMID: 25125216
http://archopht.jamanetwork.com/article.aspx?articleid=1895298
- ClinicalTrials.gov
Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation
Positive Craniopharyngioma.
https://clinicaltrials.gov/study/NCT03224767